Filing Details
- Accession Number:
- 0001209191-19-062290
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-12-31 16:37:32
- Reporting Period:
- 2019-12-27
- Accepted Time:
- 2019-12-31 16:37:32
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1107421 | Ziopharm Oncology Inc | ZIOP | Pharmaceutical Preparations (2834) | 841475642 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1641506 | Neil James Laurence Cooper | C/O Ziopharm Oncology, Inc. One First Avenue, Parris Bldg. 34 Boston MA 02129 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-12-27 | 44,642 | $2.24 | 1,843,967 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-12-30 | 110,694 | $4.88 | 1,733,273 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2019-12-27 | 44,642 | $0.00 | 44,642 | $2.24 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 487,171 | 2029-01-06 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to satisfy withholding tax obligations upon the vesting of restricted stock grants.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.79 to $5.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 1/12th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2018.
Billionaire Hedge Funds
